Detalhe da pesquisa
1.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology
; 165(6): 1443-1457, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659673
2.
Qualitative and Psychometric Evaluation of PROMIS®-29 to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease.
Value Health
; 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843977
3.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134323
4.
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
Am J Respir Crit Care Med
; 199(4): 489-495, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30346831
5.
IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
Pediatr Allergy Immunol
; 30(8): 817-823, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31437325
6.
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Pulm Pharmacol Ther
; 43: 39-45, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28159511
7.
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Lancet Gastroenterol Hepatol
; 8(4): 307-320, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738762
8.
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
J Patient Rep Outcomes
; 7(1): 115, 2023 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962770
9.
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
J Crohns Colitis
; 17(7): 1066-1078, 2023 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738443
10.
Association of B-cell activating factor receptor deficiency with the P21R polymorphism and common variable immunodeficiency.
Ann Allergy Asthma Immunol
; 115(1): 82-3, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26012370
11.
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
J Allergy Clin Immunol Pract
; 7(2): 589-596.e3, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30193936
12.
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Chest
; 150(4): 789-798, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27056586